SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

China Independent Clinical Laboratory Industry Report,2013-2015

LONDON, March 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

China Independent Clinical Laboratory Industry Report,2013-2015

Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clinical laboratory market only values RMB2.5-3 billion, equivalent to 2%-3% of the total revenue of medical diagnosis, much lower than 30% in developed countries.

However, in the context of Chinese medical reform, the cost control of public hospitals, the increasing number of patients that primary medical institutions are confronted with, the rapid development of private hospitals and other factors will greatly boost China independent clinical laboratory industry which will grow at a rate over 40%.

The report focuses on the operation, advantages and characteristics of 10 major independent clinical laboratory companies in China on the basis of an analysis on the development environment, the market situation, the competition pattern, the impact of upstream and downstream as well as the prospect of China independent clinical laboratory industry.

In China, among about 110 laboratories engaged in independent medical diagnosis, top four ones, namely Kingmed Diagnostics, ADICON, DiAn Diagnostics and DaAn Health, master more than 70% domestic market share together, all with the chain integrated diagnostic service mode.

As a giant in China independent clinical laboratory industry, Kingmed Diagnostics has maintained a revenue growth rate of more than 50% in the past five years. It achieved the revenue of over RMB1 billion in 2012 with 21 laboratories, over 13,000 clients (including more than 1,000 Grade-A hospitals) and 1,600 types of inspection services. Moreover, the company has received two rounds of capital injection from Lenovo, and always stood at the leading position of the industry.

ADICON and DiAn Diagnostics are located in the second echelon in the industry.

ADICON targets at the high-end field (including 220 special inspection items), with 15 laboratories, only second to Kingmed Diagnostics. In June 2012, the subsidiary Hefei ADICON became a designated cervical and breast cancer diagnosis institution in Hefei by virtue of the strong and efficient diagnostic service network.

China's first listed independent clinical laboratory enterprise DiAn Diagnostics gained the revenue of RMB414 million from independent medical diagnostic services in 2012, up 52.2% year on year. DiAn Diagnostics shows significant unique competitive advantages, reflected in hierarchical management and "agency + services" business model. As of the end of 2012, DiAn Diagnostics owned 13 independent diagnostic laboratories, and planned to establish 15 Class-A laboratories and 30 Class-B ones by 2016 for the purpose of the overall improvement in the service response speed.

1 Overview of Independent Medical Diagnosis
1.1 Definition
1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry
2.1 Policy
2.1.1 Access Policy
2.1.2 Industrial Policy
2.2 Impact of International Market
2.2.1 Market Situation
2.2.2 Key Enterprises
2.3 Status Quo
2.4 Competition Pattern
2.5 Development Prospect and Trend

3 Upstream and Downstream of China Independent Clinical Laboratory Industry
3.1 Impact of Upstream Market
3.1.1 Market Situation
3.1.2 Competition Pattern
3.2 Impact of Downstream Development
3.2.1 Huge Independent Medical Diagnosis Market
3.2.2 Health Care Reform Propels the Rapid Development of the Independent Medical Diagnosis Market
3.2.3 Diversified Demand Will Promote the Upgrading of the Independent Clinical Laboratory Industry

4 Major Independent Clinical Laboratory Enterprises in China
4.1 Kingmed Diagnostics
4.1.1 Profile
4.1.2 Status Quo and Prospect
4.2 Hangzhou ADICON
4.3 DiAn Diagnostics
4.3.1 Profile
4.3.2 Operation
4.3.3 Business Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 R & D and Investment
4.3.7 Independent Medical Diagnostic Services
4.3.8 Development Prospect and Trend
4.4 Da An Gene
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D
4.4.7 Independent Medical Diagnostic Services
4.5 Beijing NYMPHAVN
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients
4.5.6 R & D and Investment
4.6 CapitalBio
4.7 Beijing Adinovo
4.8 Hangzhou Zhiyuan
4.9 Kindstar Global (Beijing)
4.10 Deyi Diagnostics

Read the full report:
China Independent Clinical Laboratory Industry Report,2013-2015
http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/china_independent_clinical_laboratory_industry_report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.